6 research outputs found
Π₯ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½Π°Ρ Π±ΠΎΠ»Π΅Π·Π½Ρ Π»Π΅Π³ΠΊΠΈΡ ΠΈ COVID-19: Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠ΅ Π²ΠΎΠΏΡΠΎΡΡ
The problem of comorbidity of new coronaviral infection (COVID-19) and chronic obstructive pulmonary disease (COPD) is acute, considering similarity of clinical manifestations, diagnostic difficulties, the potential severe disease course. Patients with COPD represent a vulnerable group of infected SARS-CoV-2, with a complicated disease course and frequent adverse outcome. Features of the spread of the virus limit treatment and diagnosis for patients with COPD, making it difficult to provide medical care during the pandemic. The negative results of some clinical studies of antiviral drugs for patients with COVID-19 indicate the need for a search for new drugs; for this reason, analysis of the anti-inflammatory effect on the lungs in infection COVID-19 of drugs of basic COPD therapy is promising.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ ΠΊΠΎΠΌΠΎΡΠ±ΠΈΠ΄Π½ΠΎΡΡΠΈ Π½ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΠΎΠ½Π°Π²ΠΈΡΡΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ COVID-19 ΠΈ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΠ±ΡΡΡΡΠΊΡΠΈΠ²Π½ΠΎΠΉ Π±ΠΎΠ»Π΅Π·Π½ΠΈ Π»Π΅Π³ΠΊΠΈΡ
(Π₯ΠΠΠ) ΠΎΠ±ΡΡΠ»ΠΎΠ²Π»Π΅Π½Π° ΡΡ
ΠΎΠΆΠ΅ΡΡΡΡ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉ, ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΡΡ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ, ΠΏΠΎΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΠΆΠ΅ΡΡΡΡ ΡΠ΅ΡΠ΅Π½ΠΈΡ ΠΈ Π²Π·Π°ΠΈΠΌΠΎΠΎΡΡΠ³ΠΎΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠΈΡ
ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΉ. ΠΠΎΠ»ΡΠ½ΡΠ΅ Π₯ΠΠΠ, ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ SARS-CoV-2, ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΡΡ ΡΠΎΠ±ΠΎΠΉ ΡΡΠ·Π²ΠΈΠΌΡΡ Π³ΡΡΠΏΠΏΡ Π»ΠΈΡ Ρ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½Π½ΡΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΈ ΡΠ°ΡΡΠΎ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΈΡΡ
ΠΎΠ΄ΠΎΠΌ Π±ΠΎΠ»Π΅Π·Π½ΠΈ. ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡ Π²ΠΈΡΡΡΠ° Π½Π°ΠΊΠ»Π°Π΄ΡΠ²Π°ΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΡ Π½Π° ΠΌΠ½ΠΎΠ³ΠΎΡΠΈΡΠ»Π΅Π½Π½ΡΠ΅ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ Π»Π΅ΡΠ΅Π±Π½ΡΠ΅ ΠΌΠ΅ΡΠΎΠΏΡΠΈΡΡΠΈΡ ΠΏΡΠΈ Π₯ΠΠΠ, Π·Π°ΡΡΡΠ΄Π½ΡΡ ΠΎΠΊΠ°Π·Π°Π½ΠΈΠ΅ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈ Π±ΠΎΠ»ΡΠ½ΡΠΌ Π΄Π°Π½Π½ΠΎΠΉ ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΈ Π² ΠΏΠ΅ΡΠΈΠΎΠ΄ ΠΏΠ°Π½Π΄Π΅ΠΌΠΈΠΈ Π½Π° Π²ΡΠ΅Ρ
Π΅Π΅ ΡΡΠ°ΠΏΠ°Ρ
. ΠΠ΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΠΏΠΎΠΈΡΠΊΠ° Π½ΠΎΠ²ΡΡ
ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ΅ΡΠ΅Π½ΠΈΠΉ ΠΏΡΠΎΠ΄ΠΈΠΊΡΠΎΠ²Π°Π½Π° ΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌΠΈ ΡΠ΅ΠΊΡΡΠΈΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡΠ΄Π° ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
COVID-19; ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅ΡΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π½Π° SARS-CoV-2 ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π±Π°Π·ΠΎΠ²ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π₯ΠΠΠ Ρ Π΄ΠΎΠΊΠ°Π·Π°Π½Π½ΡΠΌ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌ Π΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ΠΌ Π½Π° Π±ΡΠΎΠ½Ρ
ΠΎΠ»Π΅Π³ΠΎΡΠ½ΡΡ ΡΠΈΡΡΠ΅ΠΌΡ
ΠΠΊΠ°Π·Π°Π½ΠΈΠ΅ ΡΠΊΡΡΡΠ΅Π½Π½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈ Π½Π° Π΄ΠΎΠ³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΠΎΠΌ ΡΡΠ°ΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°ΠΌ Ρ ΠΎΡΡΡΡΠΌ ΠΈΠ½ΡΠ°ΡΠΊΡΠΎΠΌ ΠΌΠΈΠΎΠΊΠ°ΡΠ΄Π° ΠΈ ΠΎΡΡΡΡΠΌ ΠΈΡΠ΅ΠΌΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈΠ½ΡΡΠ»ΡΡΠΎΠΌ Π² Π³ΠΎΡΠΎΠ΄Π΅ ΠΠΎΡΠΊΠ²Π΅: ΡΠΎΠ»Ρ Π°Π²ΠΈΠ°ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ Π±ΡΠΈΠ³Π°Π΄ ΡΠ΅Π½ΡΡΠ° ΡΠΊΡΡΡΠ΅Π½Π½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈ (Π’Π΅ΡΡΠΈΡΠΎΡΠΈΠ°Π»ΡΠ½ΡΠΉ ΡΠ΅Π½ΡΡ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½Ρ ΠΊΠ°ΡΠ°ΡΡΡΠΎΡ)
The increase in the number of patients with complications of cardiovascular diseases and the need for early diagnosis of such complications and the early initiation of treatment already at the prehospital stage leads to an increasingΒ need for more frequent use of helicopter medical equipment, as well as for equipping aviation medical teams with highly qualified specialists. TheΒ formation of a network of vascular invasive centers in the Moscow region,Β modern equipment and its use in air ambulance conditions require constant improvement of skills among medical workers. All this undoubtedly leads to positive results, the mortality rate from heart attacks and strokes decreases, the duration of treatment and the period of rehabilitation of patients areΒ reduced. It should be noted that even 10 years ago, medical helicopters were used in the elimination of medical consequences in road accidents, fires and emergencies. Today, aviation medical teams are involved in more than 50% of cases with cardiovascular diseases, which undoubtedly speaks of theΒ prospects for the development of medical aviation in large cities.Β Π ΠΎΡΡ ΡΠΈΡΠ»Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ, Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ Π±ΡΡΡΡΠΎΠΉ ΡΡΠ°Π½ΡΠΏΠΎΡΡΠΈΡΠΎΠ²ΠΊΠΈΒ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π² ΡΡΠ°ΡΠΈΠΎΠ½Π°Ρ Ρ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ΠΌ ΡΠ°Π½Π½Π΅ΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈΒ ΠΈ ΡΠ²ΠΎΠ΅Π²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ Π½Π° Π΄ΠΎΠ³ΠΎΡΠΏΠΈΡΠ°Π»ΡΠ½ΠΎΠΌ ΡΡΠ°ΠΏΠ΅ ΠΎΠ±ΡΡΠ»Π°Π²Π»ΠΈΠ²Π°ΡΡ Π²ΠΎΠ·ΡΠ°ΡΡΠ°ΡΡΡΡ ΠΏΠΎΡΡΠ΅Π±Π½ΠΎΡΡΡ Π² Π±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎΠΌΒ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ Π²Π΅ΡΡΠΎΠ»Π΅ΡΠ½ΠΎΠΉ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ ΡΠ΅Ρ
Π½ΠΈΠΊΠΈ ΠΈΒ Π½Π°Π»ΠΈΡΠΈΠ΅ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΡΡΠΎΠ² Π²ΡΡΠΎΠΊΠΎΠΉ ΠΊΠ²Π°Π»ΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ Π² ΡΠΎΡΡΠ°Π²Π΅Β Π°Π²ΠΈΠ°ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
Π±ΡΠΈΠ³Π°Π΄. Π€ΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅ΡΠΈ ΡΠΎΡΡΠ΄ΠΈΡΡΡΡ
Β ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΡΡ
ΡΠ΅Π½ΡΡΠΎΠ² Π² ΠΌΠΎΡΠΊΠΎΠ²ΡΠΊΠΎΠΌ ΡΠ΅Π³ΠΈΠΎΠ½Π΅, ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠ΅ ΠΎΠ±ΠΎΡΡΠ΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ Π΅Π³ΠΎ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠ°Π½ΠΈΡΠ°ΡΠ½ΠΎΠΉ Π°Π²ΠΈΠ°ΡΠΈΠΈ ΡΡΠ΅Π±ΡΡΡ ΠΏΠΎΡΡΠΎΡΠ½Π½ΠΎΠ³ΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ Π½Π°Π²ΡΠΊΠΎΠ² ΡΡΠ΅Π΄ΠΈΒ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΡ
ΡΠ°Π±ΠΎΡΠ½ΠΈΠΊΠΎΠ². ΠΡΠ΅ ΡΡΠΎ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊΒ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½ΡΠΌ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ°ΠΌ, ΡΠ°ΠΊ ΠΊΠ°ΠΊ ΡΠ½ΠΈΠΆΠ°Π΅ΡΡΡ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΡΒ ΠΎΡ ΠΈΠ½ΡΠ°ΡΠΊΡΠΎΠ² ΠΈ ΠΈΠ½ΡΡΠ»ΡΡΠΎΠ², ΡΠΎΠΊΡΠ°ΡΠ°ΡΡΡΡ ΡΡΠΎΠΊΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². Π‘Π»Π΅Π΄ΡΠ΅Ρ ΠΎΡΠΌΠ΅ΡΠΈΡΡ, ΡΡΠΎ Π΅ΡΠ΅ 10 Π»Π΅Ρ Π½Π°Π·Π°Π΄ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠ΅ Π²Π΅ΡΡΠΎΠ»Π΅ΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈΡΡ ΠΏΡΠΈ Π΄ΠΎΡΠΎΠΆΠ½ΠΎ-ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ½ΡΡ
ΠΏΡΠΎΠΈΡΡΠ΅ΡΡΠ²ΠΈΡΡ
, ΠΏΠΎΠΆΠ°ΡΠ°Ρ
ΠΈΒ ΡΡΠ΅Π·Π²ΡΡΠ°ΠΉΠ½ΡΡ
ΡΠΈΡΡΠ°ΡΠΈΡΡ
. Π‘Π΅Π³ΠΎΠ΄Π½Ρ Π°Π²ΠΈΠ°ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΈΠ΅Β Π±ΡΠΈΠ³Π°Π΄Ρ Π±ΠΎΠ»Π΅Π΅ ΡΠ΅ΠΌ Π² 50% ΡΠ»ΡΡΠ°Π΅Π² Π·Π°Π΄Π΅ΠΉΡΡΠ²ΠΎΠ²Π°Π½Ρ ΠΏΡΠΈΒ ΡΠ²Π°ΠΊΡΠ°ΡΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΡΠ΅ΡΠ΄Π΅ΡΠ½ΠΎ-ΡΠΎΡΡΠ΄ΠΈΡΡΡΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ,Β ΡΡΠΎ Π±Π΅Π·ΡΡΠ»ΠΎΠ²Π½ΠΎ Π³ΠΎΠ²ΠΎΡΠΈΡ ΠΎ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π΅Β ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠ°Π½ΠΈΡΠ°ΡΠ½ΠΎΠΉ Π°Π²ΠΈΠ°ΡΠΈΠΈ Π² ΠΊΡΡΠΏΠ½ΡΡ
Π³ΠΎΡΠΎΠ΄Π°Ρ
.
RENAISSANCE OF ARTERIAL HYPERTENSION MONOTHERAPY β THE POSITION OF THIAZIDE DIURETICS
The importance of the optimal choice of antihypertensive treatment strategy is currently widely recognised. The evidence obtained over the last five years justifies the revision of the traditional approach towards the tactics of mono- and combination antihypertensive therapy. It is essential to ensure that the patient-centred tactics of mono- and combination therapy choice is based on the detailed analysis of the clinical status
CORRECTION OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CHRONIC COR PULMONALE BY ANGIOTENSIN II RECEPTORS ANTAGONISTS
Aim. To evaluate intensity of endothelial dysfunction, processes of apoptosis, state of central and peripheral hemodynamics and to evaluate how these characteristics are influenced by angiotensin II receptors antagonists (ARA II) β candesartan (Atacand) and losartan (Cosaar) in patients with chronic cor pulmonale (CCP) at different stages of disease.Material and methods. 100 patients with chronic obstructive pulmonary disease (COPD), complicated by CCP were included into the study. Caspase activity as apoptosis induction marker, von Willebrand factor, production of nitric oxide in blood plasma and condensate of breathing out air were assessed. 70 patients received ARA II (50 patients β candesartan 4-8 mg daily, 20 patients β losartan 50-100 mg daily), 30 patients received neither ARA II nor angiotensin converting enzyme inhibitors (ACEI).Results. Significant increase in intensity of endothelial dysfunction and activation of apoptosis processes were registered according to growth of CCP severity. After 6 months of therapy von Willebrand factor decreased by 25,2% and 27,7% in candesartan and losartan groups respectively (p<0.01 for both groups). In the control group only 13.2% of von Willebrand factor reduction was seen.Conclusion. ARA II added to common therapy of COPD complicated by CCP improves functional state of endothelium restricting hyperproduction of nitric oxide and its toxic effects and slowing down apoptotic cell death
CORRECTION OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CHRONIC COR PULMONALE BY ANGIOTENSIN II RECEPTORS ANTAGONISTS
Aim. To evaluate intensity of endothelial dysfunction, processes of apoptosis, state of central and peripheral hemodynamics and to evaluate how these characteristics are influenced by angiotensin II receptors antagonists (ARA II) β candesartan (Atacand) and losartan (Cosaar) in patients with chronic cor pulmonale (CCP) at different stages of disease.Material and methods. 100 patients with chronic obstructive pulmonary disease (COPD), complicated by CCP were included into the study. Caspase activity as apoptosis induction marker, von Willebrand factor, production of nitric oxide in blood plasma and condensate of breathing out air were assessed. 70 patients received ARA II (50 patients β candesartan 4-8 mg daily, 20 patients β losartan 50-100 mg daily), 30 patients received neither ARA II nor angiotensin converting enzyme inhibitors (ACEI).Results. Significant increase in intensity of endothelial dysfunction and activation of apoptosis processes were registered according to growth of CCP severity. After 6 months of therapy von Willebrand factor decreased by 25,2% and 27,7% in candesartan and losartan groups respectively (p<0.01 for both groups). In the control group only 13.2% of von Willebrand factor reduction was seen.Conclusion. ARA II added to common therapy of COPD complicated by CCP improves functional state of endothelium restricting hyperproduction of nitric oxide and its toxic effects and slowing down apoptotic cell death.</p